Digital health and biotech company Viome Life Sciences has raised $67 million in series C financing.
The funding round comes after Viome launched its CancerDetect test as an at-home diagnostic tool for oral and throat cancers. The capital will be used to expand clinical research into chronic disease and cancer diagnostics, according to an Oct. 18 Viome news release.
The funding round was led by Bold Capital Group and brings Viome's total funding to more than $150 million.
"With our unique approach and unparalleled insight into the human microbiome and its interaction with the human host, we have helped nearly half a million individuals better understand how to take control of their health and address many underlying causes of inflammation and microbial imbalance, both of which science continues to strongly link to the onset of chronic disease," Viome Life Sciences founder and CEO Naveen Jain. "With such an obvious gap between the healthcare market and the ability to make breakthrough test solutions, such as CancerDetect, available faster to save more lives, we are thankful to our investors, who support us in each critical milestone towards our mission to help individuals live a longer, healthier life."